Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: A comparative review

Clinical Pharmacokinetics

Volumn 40, Issue 3, 2001, Pages 189-205

  Jhee, Stanford S ^a   Shiovitz, Thomas ^a   Crawford, Aaron W ^a   Cutler, Neal R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ANXIETY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSPNEA; FOOD DRUG INTERACTION; HEART PALPITATION; HUMAN; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0035060126     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140030-00004     Document Type: Review

References (5)

1. Meyer JS, Zetusky W, Jonsdottir M, et al. Cephalic hyperemia during migraine headaches: a prospective study. Headache 1986; 26: 388-97
2. Weitzel KW, Thomas ML, Small RE, et al. Migraine: a comprehensive review of new treatment options. Pharmacotherapy 1999; 19: 957-73
3. Silberstein SD. Serotonin (5-HT) and migraine. Headache 1994; 34: 408-17
4. Humphrey P, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991; 12: 444-6
5. 1D alpha serotonin receptor gene expression in trigeminal ganglia: Implications for antimigraine drug development. Proc Natl Acad Sci U S A 1994; 91: 3666-9